← Leaderboards
Ethan Vincent Abel
Roswell Park Cancer Institute Corp
$1,441,755
Attributed
$1,441,755
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $518.9K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,441,755 · 1
By mechanism
R37$1,441,755 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Fengzhi Li$3,917,805
- Joyce Ellen Ohm$5,554,830
- Zhihong Gong$2,618,766
- Carl W Porter$5,047,582
- Yan Dong$835,097
Others in their field
Other Rising Stars on “Affect”
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Thomas K Karikari · Wake Forest University Health Sciences$14,340,584
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Brian Todd Schaneberg · Illinois Institute Of Technology$13,469,813
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
Research focus
AffectApoptosisBcl2 GeneBiologyBromodomainBromodomains And Extra-Terminal Domain InhibitorCancer CellCancer EtiologyCancer Stem CellCancer TypeCell Cycle ProgressionCell DeathCell GrowthCell LineCell ProliferationCellsCell SurvivalCessation Of LifeChip-SeqClinicCombinatorialConventional TherapyDrug ResistanceAblation
Grant awards (3)
Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma$518,878
R37 · FY2025 · CA · contact PI
Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma$449,607
R37 · FY2024 · CA · contact PI
Targeting HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma$473,270
R37 · FY2023 · CA · contact PI